Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 6:7:F1000 Faculty Rev-1196.
doi: 10.12688/f1000research.14116.1. eCollection 2018.

Recent advances in the understanding and treatment of acute myeloid leukemia

Justin Watts  1 , Stephen Nimer  1
Affiliations
Review

Recent advances in the understanding and treatment of acute myeloid leukemia

Justin Watts et al. F1000Res. .

Abstract

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease that has a poor prognosis. Recent advances in genomics and molecular biology have led to a greatly improved understanding of the disease. Until 2017, there had been no new drugs approved for AML in decades. Here, we review novel drug targets in AML with a focus on epigenetic-targeted therapies in pre-clinical and clinical development as well as the recent new drug approvals.

Keywords: acute myeloid leukemia (AML); genomics; epigenetics; targeted therapies; drug development.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Justin Watts has served as a consultant and on the Speaker’s Bureau for Jazz Pharmaceuticals. He has received research funding from Takeda.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

References

    1. https://seer.cancer.gov/statfacts/html/amyl.html
    1. Juliusson G, Antunovic P, Derolf A, et al. : Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–87. 10.1182/blood-2008-07-172007 - DOI - PubMed

    2. F1000 Recommendation

    1. Slovak ML, Kopecky KJ, Cassileth PA, et al. : Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075–83. - PubMed
    1. Tallman MS, Gilliland DG, Rowe JM: Drug therapy for acute myeloid leukemia. Blood. 2005;106(4):1154–63. 10.1182/blood-2005-01-0178 - DOI - PubMed
    1. Burnett AK, Milligan D, Goldstone A, et al. : The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol. 2009;145(3):318–32. 10.1111/j.1365-2141.2009.07604.x - DOI - PubMed

Publication types

MeSH terms